

Pharmacotherapy for seizures in infants with hypoxic-ischemic encephalopathy

Elissa Yozawitz ¹, Arthur Stacey ², Ronit M. Pressler ^{3,4}

1. Department of Neurology and Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
2. UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
3. Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, Great Ormond Street, London WC1N 3JH, UK
4. Clinical Neurosciences, UCL-Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.

Corresponding author:

Ronit M Pressler, PhD MD MRCPCH
Reader in Clinical Neuroscience
UCL- Great Ormond Street Institute of Child Health
London WC1N 1EH
r.pressler@ucl.ac.uk

Abstract:

Seizures are common in neonates with moderate and severe hypoxic ischemic encephalopathy (HIE) and independently of HIE severity associated with worse outcome. In contrast to adults and older children, no new drugs have been licensed for treatment of neonatal seizures over the last 50 years due to a lack of controlled clinical trials. Hence, many anti-seizure medications licensed in older children and adults are used off-label for neonatal seizure which is associated with potential risks of adverse effects during a period when the brain is particularly vulnerable. Phenobarbital is worldwide the first line drug and considered standard of care although there is limited evidence base of its efficacy. Second line agents include phenytoin, benzodiazepines, levetiracetam and lidocaine. These drugs are discussed in more detail as well as two emerging drugs (bumetanide and topiramate). More safety, pharmacokinetic, and efficacy data are need from well-designed clinical trials to develop safe and effective antiseizure regimes for the treatment of neonatal seizures in HIE.

Key Points:

- Seizures are common in the neonatal period with up to 60% of neonatal seizures caused by hypoxic-ischemic encephalopathy (HIE) in the term infant.
- Phenobarbital is used worldwide as a first line drug for neonatal seizures despite there being limited evidence base for its efficacy.
- Second line agents used for neonatal seizures include phenytoin, benzodiazepines, levetiracetam and lidocaine, all of which are used off label.

1. Introduction

At an incidence of 1 – 5 per 1,000 live births, seizures are the most common neurological emergency in full-term newborns [1, 2]. As many as 60% of neonatal seizures present as a result of hypoxic-ischemic encephalopathy (HIE), a form of brain injury typically resulting from perinatal asphyxia [3]. Many of these seizures resolve once the underlying etiology is corrected or the acute event subsides. The neonatal brain is dynamic and therefore vulnerable to acute seizures and subsequent epileptogenesis. In HIE, neonatal seizures may exacerbate the injury caused from hypoxic ischemia. Experimental models suggest that the combination of hypoxic-ischemia and drug induced seizures increase hippocampal brain damage compared to those with hypoxic ischemic injury alone [4, 5]. Clinical studies have shown HIE to result in progressive decline in mitochondrial aerobic metabolism and subsequent loss of high-energy phosphate compounds [6, 7].

Seizures, regardless of etiology, are independently associated with increased morbidity and mortality). Moreover, seizures in the setting of HIE are associated with poor neurodevelopmental outcome, independent of HIE severity [8], more severe hippocampal cell death [9], and elevated serum concentrations of interleukin-8, an inflammatory cytokine that increases seizure susceptibility and induces organ damage [10].

2. Diagnosis

Challenges in diagnosis are a major obstacle to treatment of neonatal seizures. Clinical diagnosis is not reliable because seizures in neonates are often subclinical (sometimes named silent, occult, or electrographic-only seizures) and because manifestations are often difficult to distinguish from other movements in babies [10-12]. Furthermore, the phenomenon of electroclinical dissociation or uncoupling means that clinical seizure will become subclinical following drug administration [13]. The gold standard for diagnosis is continuous video electroencephalogram (cEEG) [14]. In clinical settings where cEEG is not available, amplitude integrated EEG (aEEG) may be used. This is not acceptable for drug development as up to 30% of seizures are missed with aEEG and movement may cause false positive errors [15, 16].

3. Treatment

Most neonatal seizures are acute reactive seizures rather than an epileptic syndrome. An important distinction should be made between the two: neonates may have acute seizures secondary to HIE, but not epilepsy, which is characterized by two or more unprovoked seizures [17]. Anti-seizure medications are typically used for management of neonatal seizures meaning they suppress seizures, not to prevent/cure epilepsy.

Numerous surveys on current practice have shown that phenobarbital is used as the first line drug world-wide while the choice of second line drug varies between and within countries [18-23]. Apart from phenobarbital no drug is currently licensed for use in neonates due to the absence of double blind placebo controlled trials. Consequently, many of the same anti-seizure medications given to older children and adults are used off-label for neonatal seizure [24]. The American Academy of Pediatrics advised that “the off label use of a drug should be based on sound scientific evidence, expert medical judgment, or published literature” [25]. There is also a

paucity of research examining pharmacological management of seizures exclusively in neonates with HIE, and what data is available is often based on animal models or retrospective case studies. Considering the potential for these drugs to produce adverse effects during a period when the brain is particularly vulnerable, more safety, pharmacokinetic, and efficacy data is needed. Neonates with HIE represent an especially difficult population to treat. Perinatal systemic ischemia often causes significant damage outside the nervous system, resulting in multi-organ dysfunction [26] which can affect metabolism of many common drugs, making their safety for use in this population even more uncertain.

Over the last 15 years three systematic reviews on the efficacy of antiseizure medication for neonatal seizures have been published [27-29] in addition to a systematic review of the pharmacokinetics [30]. All of these agree that there is little or no evidence from well conducted randomized controlled trials for the use of any anti-seizure drugs for seizures in this age group. This has not changed over the last few years (Table 1).

In the World Health Organization guidelines on neonatal seizures [29], four recommendations regarding treatment were formulated despite the acknowledged weak evidence. In summary, it is recommended that phenobarbital should be used as the first line agent for the treatment of neonatal seizures (strong recommendation). However only a weak recommendation was made concerning the choice of the second-line agent, suggesting that benzodiazepines, phenytoin or lidocaine could be used if seizures persist despite maximal tolerated doses of phenobarbital. These drugs plus a few a few more recently emerging antiseizure agents are discussed in more detail (Table 2).

3.1. Phenobarbital

Phenobarbital is a long acting barbiturate that has long been considered the standard first-line agent for neonatal seizures, likely due to its success in suppressing seizures in children and adults [19]. It is considered standard of care. Since therapeutic hypothermia (cooling) has become standard of care for HIE, many studies have examined the use of phenobarbital in combination with hypothermia for seizure control and neuroprotection. Its neuroprotective benefits have been described in animal [31] and clinical studies of HIE [32].

3.1.1 Mode of action

Phenobarbital enhances GABA_A inhibitory activity, and may limit glutamate excitation [33]. It is thought that there is an excitatory effect of GABA activity in the immature brain. Animal studies have revealed varied levels of Cl⁻ transporters in different brain regions, resulting in differing intracellular Cl⁻ concentrations. Specifically, thalamic neurons generally maintain low Cl⁻ concentrations and will be inhibited by GABA receptor activation, while concentrations are relatively high in cortical neurons. These cells, therefore, are excited by GABA activity [34]. This research suggests that other brain regions may also maintain low Cl⁻ concentrations despite their immaturity, and that phenobarbital could suppress seizures depending on the site of seizure genesis in the neonatal brain. However, recent studies have questioned whether this is a real phenomenon in vivo [35].

3.1.2 Pharmacokinetics

Phenobarbital is metabolized by the liver and excreted via the kidneys, therefore these processes may be impaired in neonates with hepatic or renal dysfunction after HIE. The drug is 40-60% bound to plasma proteins.

Comparisons of phenobarbital treatment in neonates with or without birth asphyxia reveal differences in drug processing, namely reduced clearance and higher minimum blood concentrations [36, 37]. Clinical investigations of asphyxiated newborns have found clearance values of 4.1 +/- 1.0 mL/kg/h [36], 0.0034 L/h/kg [38], and 0.08 +/- 0.03 mL/min/kg [39], suggesting that these patients require only about half the maintenance dose of non-asphyxiated newborns to achieve similar blood concentrations. The potential effect of hypothermia on phenobarbital pharmacokinetics is also controversial [40, 41]. In a prospective study of asphyxiated newborns monitored by aEEG, van den Broek and co-workers [42] found no clinically relevant effect of hypothermia on phenobarbital pharmacokinetics. Others have demonstrated changes in pharmacokinetics [40] with elevated plasma concentrations and longer half-lives compared to normothermic newborns, although hypothermia may not affect phenobarbital clearance or volume of distribution [41].

3.1.3 Efficacy

It is also the only drug strongly recommended in the WHO guideline, notably with very low evidence [29]. Phenobarbital has been shown to be incompletely effective in treatment of neonatal seizures resulting from varied etiologies, controlling seizures in only 43% of babies monitored electrographically [43]. Other studies have demonstrated control of clinical seizures in up to 70% of subjects [44], but trials specifically of newborns with HIE are more scarce. There is evidence, that phenobarbital increases the electroclinical dissociation [45], possibly due to differences in cortical versus subcortical GABAergic signaling [34].

A blood concentration reference range for phenobarbital of around 10-40 mg/L has been recommended [46], and a broad scope of blood levels have been reported as sufficient to control neonatal seizures resulting from any etiology. Titration of dosages to achieve levels up to 40-60 mg/L can be necessary in refractory cases. Seizures were controlled only when blood phenobarbital concentrations reached 17 mg/L in one study [47], while other studies have found blood concentrations of 12 to 30 mg/L to sufficiently manage neonatal seizures [48]. Much higher concentrations have been used for neonatal seizures [44, 49], but the efficacy of phenobarbital appears to plateau at concentrations around 40 to 45 mg/L. Resistant seizures should be treated

with a second-line anticonvulsant instead of increasing the concentration of phenobarbital further [44, 50]. Phenobarbital can increase electro-clinical dissociation [13].

3.1.4 Dosing

The usual loading dose of phenobarbital is 20 mg/kg IV, and may be repeated if needed. The initial maintenance dose is 3 to 5 mg/kg/day which can be given orally or intravenously. It is available for oral use in tablet and elixir form as well as in vials of sterile solution for parenteral use.

3.1.5 Adverse events

Phenobarbital has an adequate safety profile for use in asphyxiated neonates. Intravenous administration of 40 mg/kg phenobarbital over one hour did not adversely affect heart rate, respiratory rate, blood pressure, or blood gas values [32]. Painter and colleagues [43] also report that free plasma phenobarbital concentrations of 25 mg/L were not associated with similar complications. However, adverse events of irritability, sedation, hypotension, respiratory suppression or hepatotoxicity can occur and should be appropriately monitored for. Animal studies have indicated that phenobarbital may lead to neuronal apoptosis at blood levels used for seizure control [51], raising concerns about its possible effect on the developing brain. It has been shown that exposure to phenobarbital is associated with worse neurodevelopmental outcomes at 2 years of age when compared to levetiracetam [52].

3.1.6 Conclusion

Phenobarbital remains the standard first-line pharmacotherapy for neonatal seizures resulting from HIE, even though data indicate it is only effective in 50-60%. It is safe for use in this population.

3.2. Phenytoin

Phenytoin is a sodium channel blocker. The phenytoin precursor, fosphenytoin, may be an alternative to phenytoin when used intravenously due to reduced irritation at the injection site as well as lowered incidence of cardiac arrhythmias. Phenytoin is a successful anticonvulsant similar to phenobarbital in efficacy against seizures [43].

Mode of action

Phenytoin acts by stabilizing sodium channels and reducing electrical conductance across the membrane. It acts on excessive neuronal firing as opposed to barbiturates. Phenytoin stimulates the Na⁺ pump and inhibits the passive Na⁺ influx, which prolongs the inhibitory postsynaptic potentials (IPSPs). It also inhibits the Ca²⁺ influx.

Pharmacokinetics

Ninety-five percent of the drug is metabolized by the liver and is protein bound. Both enzyme inhibiting and inducing co-medication can affect its plasma concentration. Phenytoin demonstrates first order kinetics at very

low plasma concentrations and zero order at high concentrations, and this nonlinear pharmacokinetics makes it difficult to determine an appropriate phenytoin dosage in neonates [53, 54]. Half-life ($T_{1/2}$) is variable in the neonatal period with a range of 6-200 hours and longer in the first week (up to 200 hours) compared to week 2-4 (5-10 hours) [55].

Efficacy

In a randomized crossover study, phenobarbital controlled seizures in 43%, where phenytoin controlled seizures in 45% [43]. Another study assessed electrographic response to phenobarbital (40 mg/kg) followed by phenytoin (15–20 mg/kg) [56]. Seizure cessation was achieved in 5 of the 32 patients (16%) within 120 minutes following the addition of phenytoin. This is similar to a prospective study without EEG [57]. Phenytoin can increase electro-clinical dissociation [13].

Dosing

The usual loading dose of 15 to 20 mg/kg IV is recommended of fosphenytoin. Maintenance dosing is 4 to 8 mg/kg/day. A typical therapeutic dosage range for phenytoin is 10 to 20 mg/L. It is available in many forms that include chewable tablets, extended release capsules, oral suspension, and injection solution. However with oral administration it may be difficult to achieve appropriate and stable therapeutic plasma concentrations [58].

Adverse Effects

Common dose-related effects described in older children and adults include nystagmus and tremor; in neonates, hypotension, bradycardia and sedation have been described. It is capable of causing drug-induced allergic reactions such as a life-threatening dermatological (Stevens-Johnson syndrome or toxic epidermal necrolysis) and haematological conditions but this has not been described in neonates. Cardiac toxicity is related to rapid infusion rate and has not been reported in neonates. Its precursor fosphenytoin may be used as an alternative because of producing less irritation at the injection site.

Conclusion

Phenytoin/fosphenytoin is an important antiseizure medication to use in this population. It is mostly used as second line medication although there is evidence for efficacy from one RCT [43]. However, few other studies have confirmed the efficacy of phenytoin.

3.3. Benzodiazepine

Benzodiazepines are GABA agonists at the GABA_A receptors resulting in sedative-hypnotic properties as well as an anxiolytic and muscle relaxant. Diazepam, lorazepam, clobazam, midazolam and clonazepam are commonly employed for treating neonatal seizures. Midazolam is the most frequently used in neonates in the acute setting.

Mode of action

Benzodiazepines act at the gamma-aminobutyric acid (GABA) - A receptor [59] by increasing the affinity of GABA and its receptor, which increases the opening frequency of the GABA-A receptor to suppress the spread of ictal discharge. The GABA-A receptor is a ligand gated chloride-selective ion channel.

Pharmacokinetics

Benzodiazepines have a rapid onset of action and a short duration of effect. The half-life is typically 3.3-fold longer and the clearance is 3.7-fold smaller in healthy neonates than in adults [60]. Clearance of midazolam is lower in neonates than in older children and adults [61]. Multiple organ failures as well as the presence of disease reduce its clearance. Mechanical ventilation prolongs its half-life [60]. Most benzodiazepines are highly protein bound. They are oxidatively metabolized by the cytochrome P450 enzymes (phase I), conjugated with glucuronide (phase II), and excreted almost entirely in the urine. The function of cytochrome P450 increases throughout the first year of life.

Efficacy

Some retrospective studies suggested excellent efficacy of midazolam [62, 63], but this was not confirmed in other retrospective studies [64, 65]. In a prospective study that looked at midazolam in HIE term babies, it was found that following phenobarbital and lidocaine, a load of midazolam followed by maintenance revealed seizure cessation within 24 hours in 11 of 15 subjects (73%). No significant side effects were reported [66]. When a single dose of lorazepam was added to phenobarbital and phenytoin in seven infants, three of the neonates with continuous EEG monitoring had seizure cessation within 5 minutes following lorazepam [67]. Diazepam efficacy is less than that of phenobarbital [68].

Dosing

Dosing recommendations vary. Midazolam loading dose is between 0.05 and 0.15 mg/kg followed by a maintenance dose of 0.05 mg/kg/hour and increased as needed up to a maximum of 0.4 mg/kg/hour IV. Diazepam is administered orally at a dose of 0.1-0.5 mg/kg IV or rectally at a dose of 0.5 mg/kg/dose. Lorazepam can also be given in the acute setting, at a dose of 0.05-0.1 mg IV with a repeat dose of 0.05 mg in 10 minutes.

Adverse Effects

Since benzodiazepines are typically used in the acute setting, it is important to consider that disease may affect its pharmacokinetics in the neonates. Respiratory depression and hypotension appear in a limited number of babies who receive intravenous injection. It is more common when used with narcotics or when administered by rapid bolus. Hypotension is more common with continuous infusion. Pain, tenderness, and thrombophlebitis have occurred following injection of midazolam. Particularly in preterm infants myoclonus has been observed in associated with midazolam treatment [69]. More recently concerns have been raised that use of benzodiazepines in the neonatal period may negatively impact brain development [70].

Conclusion

Benzodiazepines are best used in the acute setting and are typically discontinued prior to the patient's discharge from hospital. They are relatively safe when monitored appropriately and are typically used in refractory cases to first line treatment.

3.4. Levetiracetam

Levetiracetam has efficacy as both monotherapy [71] and adjunctive therapy for patients as young as 4 years of age [72]. Despite limited data on children less than 1 year of age, off label use is employed. It may be administered as either a tablet or intravenous formulation. Despite lack of efficacy data from randomized controlled trials, it is used as first line medication for neonatal seizures in several centers, particularly in Germany and Switzerland.

Mode of action

Levetiracetam is mechanistically different to most anti-seizure medication and its complete mode of action is still not fully understood. It appears to exert its effect presynaptically by impeding synaptic vesicle trafficking. The binding target of levetiracetam is synaptic vesicle protein 2A (SV2A), which is expressed throughout all brain regions and is involved in exocytosis of neurotransmitters [73, 74].

Pharmacokinetics

Levetiracetam has a very favorable pharmacokinetic profile, characterized by >95% bioavailability, is not protein bound to plasma protein, rapidly achieves steady-state concentration (24-48 h), and is not metabolized by the CYP P450 system. Clearance occurs through renal systems with 66% excreted unchanged in the urine, and 34% metabolized primarily by hydrolysis in the blood [75-77]. Consequently, dosage adjustments should be considered in patients with renal dysfunction because total body clearance is likely decreased. There are currently no published data of levetiracetam pharmacokinetics in neonates with exclusively HIE-induced seizures. Available data for babies with seizures from any etiology reveal that the clearance, half-life, and volume of distribution were increased in neonates compared to older children [78, 79].

Efficacy

A lack of randomized controlled trials makes efficacy of levetiracetam difficult to assess for this population. The data available is mostly from retrospective case studies and indicate levetiracetam has good efficacy as a second-line medication for seizures refractory to phenobarbital. Case studies have demonstrated seizure reduction or seizure freedom after receiving levetiracetam in the acute setting [80-83]. However, one study has suggested that levetiracetam may be less efficacious for neonatal seizures after severe HIE than seizures from other etiologies [84]. Overall efficacy ranges from 30 to 86% in uncontrolled studies [82, 85]. Three randomized controlled trials are now underway to test efficacy in neonatal seizures as first line drug (Clinical trials: NCT01720667, NCT03107507, and NCT02550028).

Adverse events

Several retrospective studies have reported no levetiracetam-related adverse events [80-82, 84, 86]. Specifically, no adverse respiratory, cardiovascular, hematological, renal or hepatic effects were observed. Experimental studies have shown that exposure to levetiracetam does not increase apoptosis in white matter of examined brain regions compared to saline-treated rats [87]. Animal studies suggest that levetiracetam may be neuroprotective against apoptotic cell death after hypoxia [88], although this is controversial [89]. Mildly low platelet counts have been reported following levetiracetam treatment in one prospective study [79]. Other commonly reported side-effects in the pediatric population are somnolence and behavioral changes, particularly irritability [78, 84, 90, 91].

Conclusions

Given its favorable pharmacokinetic, efficacy, and safety data, levetiracetam is a contender for a second-line medication when seizures are refractory to phenobarbital. Its use in this population is, however, limited by a lack of controlled clinical trials assessing its efficacy and pharmacokinetics specifically in newborns with HIE. There are two ongoing clinical trials which will report on efficacy, safety, and pharmacokinetics (NCT01720667; NCT02550028), including a phase 2 randomized blinded controlled trial comparing levetiracetam to phenobarbital as a first-line medication (NCT01720667). However, neither of these trials are limited to babies with HIE.

3.5. Lidocaine

Lidocaine is an amide used as local anesthetic and antiarrhythmic drug but it also has a concentration-dependent effect on seizures. At lower concentrations, lidocaine can effectively suppress seizures, whereas at high concentrations it may cause seizures. It is a popular anti-seizure drug in some European countries (Sweden, Netherlands etc.) where it is widely used as second or third line choice.

Mode of action

It suppresses seizures by inhibition of voltage-gated Na⁺ channels in presynaptic neurons. Due to its lipophilic property, it quickly passes the brain-blood barrier.

Pharmacokinetics

Lidocaine is a 'high-clearance' drug meaning that the hepatic clearance of lidocaine is determined by the hepatic blood flow and therefore reduced during hypothermia [92, 93]. The half-life is 5.2–5.4 hours.

Efficacy

Several retrospective and uncontrolled studies indicate an efficacy between 70%-92% of neonates responding to lidocaine as second line antiseizure drug [65, 94-98]. However most of these studies used aEEG rather than cEEG

and were retrospective. No randomized control trials with lidocaine exist to confirm efficacy in a controlled setting.

Dosing

The dose needs to be adjusted to bodyweight and in case of therapeutic hypothermia. This will ensure lower cumulative dosages and consequently reduce the risk of adverse cardiac effects. A dosing regimen was developed by Malingre et al. [96] and more recently updated by van den Broek et al. [93] to reduce the risk of these dose dependent events:

- In **normothermic conditions**: initial bolus loading dose of 2 mg/kg over 10 minutes. For infants with body weight 2.0–2.5 kg this is followed by continuous infusions of 6 mg/kg/h for 4 hours, then 3 mg/kg/h for 12 hours, and finally 1.5 mg/kg/h for 12 hours before stopping. For infants with bodyweights 2.5–4.5 kg, the bolus is followed by 7 mg/kg/h for 4 hours, then 3.5 mg/kg/h for 12 hours, and finally 1.75 mg/kg/h for 12 hours before stopping.
- In **hypothermic conditions**: initial bolus loading dose of 2 mg/kg over 10 minutes. For infants with body weight 2.0–2.5 kg, this is followed by continuous infusions of 6 mg/kg/h for 3.5 hours, then 3 mg/kg/h for 12 hours, and finally 1.5 mg/kg/h for 12 hours before stopping. For infants with bodyweights 2.5–4.5 kg the bolus is followed by 7 mg/kg/h for 3.5 hours, then 3.5 mg/kg/h for 12 hours, and finally 1.75 mg/kg/h for 12 hours before stopping.

Adverse Effects

Adverse events include sedation, respiratory depression and cardiovascular events including bradycardia, arrhythmias, and hypotension. Cardiac events have been described in up to 5% of neonates [96, 99, 100] and hence need to be closely monitored. It has been suggested that the cardiac effect of lidocaine are less pronounced during hypothermia [93]. A case of methemoglobinemia has recently been described in a newborn [101]. Contraindications include congenital heart disease and treatment with phenytoin.

Conclusions

Lidocaine shows promising efficacy as second- or third-line treatment for neonatal seizures but this has not been confirmed in randomized control trials. It has a narrow therapeutic window requiring cardiac monitoring and adherence to strict dosage regimes.

3.6. Bumetanide

Bumetanide is a loop diuretic with well described pharmacokinetic data and favorable safety profile in adults and children. It has been used routinely in many neonatal units in the USA for the last 30 years. More recently it has been suggested that it may also be effective in treating neonatal seizure by inhibiting neuronal NKCC co-transporters.

Mode of action

GABA_A is a major inhibitory receptor in the mature neurons. However in immature neurons, there is an overexpression of NKCC1 and underexpression of KCC2 which results in a high intracellular chloride concentration which results in depolarizing GABA_A receptor-mediated action and excitation [102]. Inhibiting NKCC1 would lower intracellular Cl⁻ concentration, thus converting GABA activity into an inhibitory process as opposed to an excitatory one. However, recent studies have questioned whether this is a real phenomenon in vivo [35]. In vitro studies suggest that bumetanide reduces or reverses the depolarizing action of GABA, resulting in reduced neuronal firing in immature neurons [103-105].

Pharmacokinetics

Most available pharmacokinetic data for bumetanide in infants is from critically ill or preterm patients given bumetanide for fluid overload [106, 107]. Elimination follows first order kinetics and other pharmacokinetic parameters such as volume of distribution, clearance, and half-life are independent of bumetanide dose [106]. Elimination appears to be slower in babies compared to adults. One study suggests that the pharmacokinetic parameters in full-term neonates with HIE is similar to published population data [108]. The half-life of bumetanide in critically ill neonates ranges from 1.74 to 7.0 hours [109] whereas in neonates with HIE undergoing therapeutic hypothermia the half-life was slightly longer (8.4 h) [108].

Efficacy

Efficacy data from animal studies look promising for the use of bumetanide in conjunction with phenobarbital. A recent experiment done in rats found that this combination of therapies was significantly more beneficial for hypoxia-induced seizures than phenobarbital alone [110]. In other studies, bumetanide showed more benefit for neonatal seizures than for seizures in postneonatal or early adolescent rats [111].

In a single case report treatment of a neonate with refractory seizures a single dose of bumetanide showed some efficacy [112].

So far only one clinical trial has been published [113]: the NEMO trial (Treatment of NEonatal seizures with Medication Off-patent) was an open label exploratory dose finding and pharmacokinetic clinical trial of bumetanide for the treatment of neonatal seizures. Neonates with HIE and seizures not responding to phenobarbital were treated with bumetanide add on for 2 days. The primary efficacy endpoint was a reduction in electrographic seizure burden of more than 80% without the need for rescue antiepileptic drugs in more than 50% of infants. The trial was terminated early due to adverse events (see below) but evaluation of efficacy data in 14 babies suggested that bumetanide did not reduce seizure burden over and above the second phenobarbital dose. This may be due to limited transfers across the brain-blood barrier [90, 114].

Dosing

No recommended dose exists for bumetanide as an antiseizure agent. The recommended dosing as a diuretic agents ranges from 0.005 to 0.1 mg/kg/day.

Adverse events

Most trials of bumetanide in newborns indicate that it is well-tolerated with a good safety profile, even in critically ill or preterm babies. Doses ranging from 0.005 to 0.10 mg/kg were tolerated well by neonates or children younger than six months, specifically without incidence of electrolyte abnormalities, hemodynamic change, hypovolemia, or hyperbilirubinemia [107, 109]. These studies, however, bumetanide was used as a diuretic and thus given to a different population in a smaller dose than what is proposed for seizures. .

In the NEMO study, no short-term dose-limiting toxic effects were reported, but three of 11 surviving infants had hearing impairment causing early termination of the trial. Results also highlighted the risks associated with the off-label use of drugs in newborn infants before safety assessment in controlled trials.

Conclusions

Although preclinical data suggest that bumetanide may have a potential as an antiseizure drug for newborns, clinical data so far is not encouraging.

3.7. Topiramate

Topiramate has been used for over a decade in children and adults as both add-on therapy [115, 116] as well as monotherapy [117]. Although it is currently approved for use in children aged two through 16 years, it is used off label in the neonatal period. Despite only having an oral formulation, its use is gaining support in this population because of its apparent neuroprotective efficacy in animals modeling hypoxic-ischemic injury [54, 118, 119].

Mode of action

Topiramate is a sulfamate-substituted monosaccharide which has multiple mechanisms of action: it enhances GABA activity, inhibits kainate-mediated conductance at glutamate receptors, and modifies Na⁺- and Ca²⁺-dependent action potentials.

Pharmacokinetics

Topiramate exhibits a linear relationship between dose and serum concentration and is not highly protein bound. Approximately 70% of the drug is eliminated unchanged in the urine. Data from children and adolescents aged 1-17 years of age indicate that infants exhibit higher clearance and shorter half-lives than older children [120, 121]. Pharmacokinetic data for topiramate in babies with HIE is more limited. One small study examined 13 term newborns undergoing hypothermia for HIE [122]. Cooled patients displayed somewhat slowed topiramate absorption and elimination when compared to normothermic babies.

Efficacy

Published data on the effect of topiramate in this neonatal seizures after HIE is scarce. Results from a recent efficacy pilot trial [123] suggests that administration of topiramate in neonates with HIE is safe but does not demonstrate neuroprotection. However, a trend towards a reduction in epilepsy was observed. Seizures during the neonatal period were not an outcome measure in this study. One small clinical study in newborns with presumed hypoxic-ischemic injury and refractory seizures had decreased or no clinical and/or electrographic seizures following treatment with topiramate [124]. However, a RCT in infants aged 1 month to 2 years with refractory partial-onset seizures topiramate did not significantly reduce seizure rates [125].

Dosing

There is no approved dosing for neonates. Initial safety data from one small sample indicate that it is safe to use in this population at a dose of 5 mg/kg, and other series indicate 10 mg/kg is tolerated as well among neonates [124, 126]. Doses of 50 mg/kg, however, may be neurotoxic [127].

Adverse Events

As of now, only an oral formulation is available. Topiramate has a good safety profile among neonates and older children [126]. For babies with HIE, doses of 10 mg/kg have caused some irritability, feeding problems with minimal weight loss, and metabolic acidosis [121, 123, 124]. Doses of 5 mg/kg in asphyxiated newborns undergoing hypothermia are tolerated well with no identified adverse events due to topiramate [122, 123]. Topiramate inhibits carbonic anhydrase, causing lowered bicarbonate levels, which can lead to metabolic acidosis. Pediatric patients are more susceptible to this effect of topiramate than adults, although cases of decreased bicarbonate have not been clinically significant [128, 129].

Conclusions

Topiramate is an emerging therapy for seizures in neonates with HIE but is currently used off-label. Initial safety data from one small sample indicate it is safe to use in this population at a dose of 5 mg/kg, and other series indicate 10 mg/kg is tolerated as well among neonates [124, 126].

4. Neuroprotection and antiseizure mediation

Some of the antiseizure medication used in the neonatal period have suspected or proven neuroprotective properties, for example phenobarbital and topiramate. The evidence has been discussed in the respective paragraphs.

Hypothermia is the current standard for neuroprotection in moderate to severe hypoxic ischemic injury in infants 36 weeks gestation and older. Two types of therapeutic hypothermia are currently used; selective head and whole body cooling. Cooling typically occurs for a duration of 72 hours followed by gradual cooling. When hypothermia is initiated within 5.5 hours after brain ischemia, it has been shown to be advantageous [130]. Hypothermia is thought to be neuroprotective by inhibiting the cascade of cell injury that culminates in cell

death. Evidence from multiple randomized control trials indicate the therapeutic hypothermia in neonates with moderate to severe HIE reduces the risk of death or disability at 18 to 22 months without significant adverse effects [131, 132]. Animal studies indicate that therapeutic hypothermia can decrease seizures and epileptiform activity in HIE [133, 134]. However, in human studies, the results have been mixed. Some studies conclude that it reduces seizure burden, as measured by cEEG [135]. However, other studies report that electrographic seizures can still be present [1, 136]. Since the introduction of therapeutic hypothermia, the mortality rate has been reduced without an increase in disability rates [132]. Although hypothermia is relatively safe [132], risk factors should be monitored for including bradycardia, hypotension, renal insufficiency, coagulopathy, electrolyte abnormalities, skin edema, immunologic changes, and rebound hyperthermia.

5. Conclusions

An ethical dilemma exists regarding the off-label use of medications to manage seizures in newborn babies. As these drugs are not licensed for children this young, we cannot ensure the safety of anti-seizure medications to the same degree as we can in older children and adults. Medications commonly used in older patients have shown adverse effects and poor neurodevelopment in babies. On the other hand, seizures themselves are dangerous and damaging. Thus, there is clearly a need to identify the optimal treatment protocol to manage seizures in this population.

Ideally, novel medications would be developed specifically for asphyxiated newborns. However, if drugs continue to be used off-label for neonates, prospective randomized controlled trials are needed to clarify precise pharmacokinetics, efficacy, and safety both in the presence and absence of therapeutic hypothermia. In addition, drug interactions of babies receiving polypharmacy are unclear. These studies must diagnose seizures electrographically and employ a large enough sample for powerful data analysis. The existing data are encouraging, but it is difficult to assess efficacy and safety without a control group for comparison, especially considering that a large portion of seizures remit on their own. The use of dried blood spots has been used in some recent drug trials for therapeutic drug monitoring [122]. Their use will improve the ease of studies in the future since the technique is a minimally invasive procedure that requires a small volume of blood from the neonate.

Based on the available literature, phenobarbital remains the standard first-line agent for neonatal seizures, despite its potentially harmful effects and limited efficacy. Possible secondary medications include phenytoin, bumetanide, topiramate, levetiracetam, lidocaine, or benzodiazepines, with no clear indication of which may be most effective. Ongoing trials of these drugs in neonates with or without HIE should provide more direction for clinicians.

Compliance with Ethical Standards

Funding

None

Conflicts of Interest

Elissa Yozawitz , Arthur Stacey and Ronit M. Pressler declared no conflict of interest.

6. References

1. Glass, H.C., et al., *Risk factors for EEG seizures in neonates treated with hypothermia: a multicenter cohort study*. Neurology, 2014. **82**(14): p. 1239-44.
2. Shetty, J., *Neonatal seizures in hypoxic-ischaemic encephalopathy--risks and benefits of anticonvulsant therapy*. Dev Med Child Neurol, 2015. **57 Suppl 3**: p. 40-3.
3. Volpe, J., *Neonatal Seizures*, in *Neurology of the Newborn*, J. Volpe, Editor. 2008, WB Saunders: Philadelphia. p. 203-44.
4. Wirrell, E.C., et al., *Prolonged seizures exacerbate perinatal hypoxic-ischemic brain damage*. Pediatr Res, 2001. **50**(4): p. 445-54.
5. Yager, J.Y., et al., *Prolonged neonatal seizures exacerbate hypoxic-ischemic brain damage: correlation with cerebral energy metabolism and excitatory amino acid release*. Dev Neurosci, 2002. **24**(5): p. 367-81.
6. Mitra, S., et al., *Changes in Cerebral Oxidative Metabolism during Neonatal Seizures Following Hypoxic-Ischemic Brain Injury*. Front Pediatr, 2016. **4**: p. 83.
7. Miller, S.P., et al., *Seizure-associated brain injury in term newborns with perinatal asphyxia*. Neurology, 2002. **58**(4): p. 542-8.
8. Glass, H.C., et al., *Clinical Neonatal Seizures are Independently Associated with Outcome in Infants at Risk for Hypoxic-Ischemic Brain Injury*. J Pediatr, 2009. **155**(3): p. 318-23.
9. Schiering, I.A., et al., *Correlation between clinical and histologic findings in the human neonatal hippocampus after perinatal asphyxia*. J Neuropathol Exp Neurol, 2014. **73**(4): p. 324-34.
10. Glass, H.C., et al., *Contemporary Profile of Seizures in Neonates: A Prospective Cohort Study*. J Pediatr, 2016. **174**: p. 98-103 e1.
11. Mizrahi, E.M. and P. Kellaway, *Characterization and classification of neonatal seizures*. Neurology, 1987. **37**(12): p. 1837-44.
12. Malone, A., et al., *Interobserver agreement in neonatal seizure identification*. Epilepsia, 2009. **50**(9): p. 2097-101.
13. Scher, M.S., et al., *Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use*. Pediatr Neurol, 2003. **28**(4): p. 277-80.
14. Shellhaas, R.A., et al., *The American Clinical Neurophysiology Society's Guideline on Continuous Electroencephalography Monitoring in Neonates*. J Clin Neurophysiol, 2011. **28**(6): p. 611-7.
15. Shellhaas, R.A., A.I. Soaita, and R.R. Clancy, *Sensitivity of amplitude-integrated electroencephalography for neonatal seizure detection*. Pediatrics, 2007. **120**(4): p. 770-7.
16. Shah, D.K., et al., *Accuracy of bedside electroencephalographic monitoring in comparison with simultaneous continuous conventional electroencephalography for seizure detection in term infants*. Pediatrics, 2008. **121**(6): p. 1146-54.
17. Fisher, R.S., et al., *ILAE official report: a practical clinical definition of epilepsy*. Epilepsia, 2014. **55**(4): p. 475-82.
18. Carmo, K.B. and P. Barr, *Drug treatment of neonatal seizures by neonatologists and paediatric neurologists*. J Paediatr Child Health, 2005. **41**(7): p. 313-6.
19. Bartha, A.I., et al., *Neonatal seizures: multicenter variability in current treatment practices*. Pediatr Neurol, 2007. **37**(2): p. 85-90.
20. Bassan, H., et al., *Neonatal seizures: dilemmas in workup and management*. Pediatr Neurol, 2008. **38**(6): p. 415-21.
21. Blume, H.K., M.M. Garrison, and D.A. Christakis, *Neonatal seizures: treatment and treatment variability in 31 United States pediatric hospitals*. J Child Neurol, 2009. **24**(2): p. 148-54.

22. Vento, M., et al., *Approach to seizures in the neonatal period: a European perspective*. Acta Paediatr, 2010. **99**(4): p. 497-501.
23. Wickstrom, R., B. Hallberg, and M. Bartocci, *Differing attitudes toward phenobarbital use in the neonatal period among neonatologists and child neurologists in Sweden*. Eur J Paediatr Neurol, 2013. **17**(1): p. 55-63.
24. Conroy, S., *Association between licence status and medication errors*. Arch Dis Child, 2011. **96**(3): p. 305-6.
25. Frattarelli, D.A., et al., *Off-label use of drugs in children*. Pediatrics, 2014. **133**(3): p. 563-7.
26. Shah, P., et al., *Multiorgan dysfunction in infants with post-asphyxial hypoxic-ischaemic encephalopathy*. Arch Dis Child Fetal Neonatal Ed, 2004. **89**(2): p. F152-5.
27. Booth, D. and D.J. Evans, *Anticonvulsants for neonates with seizures*. Cochrane Database Syst Rev, 2004(4): p. CD004218.
28. Slaughter, L.A., A.D. Patel, and J.L. Slaughter, *Pharmacological treatment of neonatal seizures: a systematic review*. J Child Neurol, 2013. **28**(3): p. 351-64.
29. WHO, *Guidelines on neonatal seizures*, WHO, Editor. 2011: Geneva.
30. Tulloch, J.K., R.R. Carr, and M.H. Ensom, *A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures*. J Pediatr Pharmacol Ther, 2012. **17**(1): p. 31-44.
31. Barks, J.D., et al., *Phenobarbital augments hypothermic neuroprotection*. Pediatr Res, 2010. **67**(5): p. 532-7.
32. Hall, R.T., F.K. Hall, and D.K. Daily, *High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up*. J Pediatr, 1998. **132**(2): p. 345-8.
33. Bialer, M. and H.S. White, *Key factors in the discovery and development of new antiepileptic drugs*. Nat Rev Drug Discov, 2010. **9**(1): p. 68-82.
34. Glykys, J., et al., *Differences in cortical versus subcortical GABAergic signaling: a candidate mechanism of electroclinical uncoupling of neonatal seizures*. Neuron, 2009. **63**(5): p. 657-72.
35. Valeeva, G., et al., *An Optogenetic Approach for Investigation of Excitatory and Inhibitory Network GABA Actions in Mice Expressing Channelrhodopsin-2 in GABAergic Neurons*. J Neurosci, 2016. **36**(22): p. 5961-73.
36. Gal, P., et al., *The influence of asphyxia on phenobarbital dosing requirements in neonates*. Dev Pharmacol Ther, 1984. **7**(3): p. 145-52.
37. Nahata, M.C., T. Masuoka, and R.C. Edwards, *Developmental aspects of phenobarbital dosage requirements in newborn infants with seizures*. J Perinatol, 1988. **8**(4): p. 318-20.
38. Sima, M., et al., *Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns*. Physiol Res, 2015. **64 Suppl 4**: p. S513-9.
39. Donn, S.M., T.H. Grasela, and G.W. Goldstein, *Safety of a higher loading dose of phenobarbital in the term newborn*. Pediatrics, 1985. **75**(6): p. 1061-4.
40. Filippi, L., et al., *Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia*. Epilepsia, 2011. **52**(4): p. 794-801.
41. Shellhaas, R.A., et al., *Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia*. Pediatr Crit Care Med, 2013. **14**(2): p. 194-202.
42. van den Broek, M.P., et al., *Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach*. Clin Pharmacokinet, 2012. **51**(10): p. 671-9.

43. Painter, M.J., et al., *Phenobarbital compared with phenytoin for the treatment of neonatal seizures*. N Engl J Med, 1999. **341**(7): p. 485-9.
44. Gilman, J.T., et al., *Rapid sequential phenobarbital treatment of neonatal seizures*. Pediatrics, 1989. **83**(5): p. 674-8.
45. Boylan, G.B., et al., *Phenobarbitone, neonatal seizures, and video-EEG*. Arch Dis Child Fetal Neonatal Ed, 2002. **86**(3): p. F165-70.
46. Patsalos, P.N., et al., *Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies*. Epilepsia, 2008. **49**(7): p. 1239-76.
47. Lockman LA, K.R., Zasko D, Thompson T, Virnig N. Lawrence, R., et al., *A pilot study of continuous limited-channel aEEG in term infants with encephalopathy*. J Pediatr, 2009. **154**(6): p. 835-841.
48. Jalling, B., *Plasma concentrations of phenobarbital in the treatment of seizures in newborns*. Acta Paediatr Scand, 1975. **64**(3): p. 514-24.
49. Crawford, T.O., et al., *Very-high-dose phenobarbital for refractory status epilepticus in children*. Neurology, 1988. **38**(7): p. 1035-40.
50. Gal, P., et al., *Efficacy of phenobarbital monotherapy in treatment of neonatal seizures -- relationship to blood levels*. Neurology, 1982. **32**(12): p. 1401-4.
51. Bittigau, P., et al., *Antiepileptic drugs and apoptotic neurodegeneration in the developing brain*. Proc Natl Acad Sci U S A, 2002. **99**(23): p. 15089-94.
52. Maitre, N.L., et al., *Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures*. J Perinatol, 2013. **33**(11): p. 841-6.
53. Al Za'abi, M., et al., *Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures*. Ther Drug Monit, 2006. **28**(6): p. 793-9.
54. Mikati, M.A., et al., *Potential neuroprotective effects of continuous topiramate therapy in the developing brain*. Epilepsy Behav, 2011. **20**(4): p. 597-601.
55. Bourgeois, B.F. and W.E. Dodson, *Phenytoin elimination in newborns*. Neurology, 1983. **33**(2): p. 173-8.
56. Bye, A. and D. Flanagan, *Electroencephalograms, clinical observations and the monitoring of neonatal seizures*. J Paediatr Child Health, 1995. **31**(6): p. 503-7.
57. Pathak, G., et al., *Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial*. Indian Pediatr, 2013. **50**(8): p. 753-7.
58. Sicca, F., et al., *Phenytoin administration in the newborn and infant*. Brain Dev, 2000. **22**(1): p. 35-40.
59. Mihi S, H.R., *Hypnotic and sedatives*, in *The Pharmacological Basis of Therapeutics*, B.C. L. Brunton, and B. Knollman, Editor. 2011, McGraw Hill: New York, NY.
60. Pacifici, G.M., *Clinical pharmacology of midazolam in neonates and children: effect of disease--a review*. Int J Pediatr, 2014. **2014**: p. 309342.
61. de Wildt, S.N., et al., *Pharmacodynamics of intravenous and oral midazolam in preterm infants*. Clin Drug Investig, 2003. **23**(1): p. 27-38.
62. Sheth, R.D., et al., *Midazolam in the treatment of refractory neonatal seizures*. Clin Neuropharmacol, 1996. **19**(2): p. 165-70.
63. Castro Conde, J.R., et al., *Midazolam in neonatal seizures with no response to phenobarbital*. Neurology, 2005. **64**(5): p. 876-9.
64. van den Broek, M.P., et al., *Anticonvulsant effectiveness and hemodynamic safety of midazolam in full-term infants treated with hypothermia*. Neonatology, 2015. **107**(2): p. 150-6.

65. Shany, E., O. Benzagen, and N. Watemala, *Comparison of continuous drip of midazolam or lidocaine in the treatment of intractable neonatal seizures*. J Child Neurol, 2007. **22**(3): p. 255-9.
66. van Leuven, K., et al., *Midazolam and amplitude-integrated EEG in asphyxiated full-term neonates*. Acta Paediatr, 2004. **93**(9): p. 1221-7.
67. Deshmukh, A., et al., *Lorazepam in the treatment of refractory neonatal seizures. A pilot study*. Am J Dis Child, 1986. **140**(10): p. 1042-4.
68. Shaner, D.M., et al., *Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin*. Neurology, 1988. **38**(2): p. 202-7.
69. Ozcan, B., et al., *Rhythmic myoclonic jerking induced by midazolam in a preterm infant*. Pediatr Neurol, 2015. **52**(6): p. e9.
70. Duerden, E.G., et al., *Midazolam dose correlates with abnormal hippocampal growth and neurodevelopmental outcome in preterm infants*. Ann Neurol, 2016. **79**(4): p. 548-59.
71. Stephen, L.J., et al., *Levetiracetam monotherapy--outcomes from an epilepsy clinic*. Seizure, 2011. **20**(7): p. 554-7.
72. Verrotti, A., et al., *Levetiracetam in childhood epilepsy*. Paediatr Drugs, 2010. **12**(3): p. 177-86.
73. Bajjalieh, S.M., et al., *Differential expression of synaptic vesicle protein 2 (SV2) isoforms*. J Neurosci, 1994. **14**(9): p. 5223-35.
74. Lynch, B.A., et al., *The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam*. Proc Natl Acad Sci U S A, 2004. **101**(26): p. 9861-6.
75. Patsalos, P.N., *Pharmacokinetic profile of levetiracetam: toward ideal characteristics*. Pharmacol Ther, 2000. **85**(2): p. 77-85.
76. Patsalos, P.N., *The pharmacokinetic characteristics of levetiracetam*. Methods Find Exp Clin Pharmacol, 2003. **25**(2): p. 123-9.
77. Patsalos, P.N., *Clinical pharmacokinetics of levetiracetam*. Clin Pharmacokinet, 2004. **43**(11): p. 707-24.
78. Merhar, S.L., et al., *Pharmacokinetics of levetiracetam in neonates with seizures*. J Pediatr, 2011. **159**(1): p. 152-154 e3.
79. Sharpe, C.M., et al., *A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life*. Pediatr Res, 2012. **72**(1): p. 43-9.
80. Abend, N.S., et al., *Levetiracetam for treatment of neonatal seizures*. J Child Neurol, 2011. **26**(4): p. 465-70.
81. Rakshasbhuvankar, A., et al., *Intravenous levetiracetam for treatment of neonatal seizures*. J Clin Neurosci, 2013. **20**(8): p. 1165-7.
82. Venkatesan, C., et al., *Levetiracetam for the Treatment of Seizures in Neonatal Hypoxic Ischemic Encephalopathy*. J Child Neurol, 2017. **32**(2): p. 210-214.
83. Furwentsches, A., et al., *Levetiracetam in the treatment of neonatal seizures: a pilot study*. Seizure, 2010. **19**(3): p. 185-9.
84. Yau, M.L., E.L. Fung, and P.C. Ng, *Response of levetiracetam in neonatal seizures*. World J Clin Pediatr, 2015. **4**(3): p. 45-9.
85. Loiacono, G., et al., *The treatment of neonatal seizures: focus on Levetiracetam*. J Matern Fetal Neonatal Med, 2016. **29**(1): p. 69-74.
86. Khan, O., et al., *Use of intravenous levetiracetam for management of acute seizures in neonates*. Pediatr Neurol, 2011. **44**(4): p. 265-9.
87. Kaushal, S., et al., *Anticonvulsant drug-induced cell death in the developing white matter of the rodent brain*. Epilepsia, 2016. **57**(5): p. 727-34.

88. Kilicdag, H., et al., *The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury*. Early Hum Dev, 2013. **89**(5): p. 355-60.
89. Strasser, K., et al., *Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain*. Brain Res, 2016. **1646**: p. 116-24.
90. Donovan, M.D., et al., *In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide*. Eur J Pharmacol, 2016. **770**: p. 117-25.
91. Pina-Garza, J.E., et al., *Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures*. Epilepsia, 2009. **50**(5): p. 1141-9.
92. van den Broek, M.P., et al., *Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures*. Clin Pharmacokinet, 2011. **50**(7): p. 461-9.
93. van den Broek, M.P., et al., *Anticonvulsant treatment of asphyxiated newborns under hypothermia with lidocaine: efficacy, safety and dosing*. Arch Dis Child Fetal Neonatal Ed, 2013. **98**(4): p. F341-5.
94. Hellstrom-Westas, L., et al., *Lidocaine for treatment of severe seizures in newborn infants. I. Clinical effects and cerebral electrical activity monitoring*. Acta Paediatr Scand, 1988. **77**(1): p. 79-84.
95. Boylan, G.B., et al., *Second-line anticonvulsant treatment of neonatal seizures: a video-EEG monitoring study*. Neurology, 2004. **62**(3): p. 486-8.
96. Malingre, M.M., et al., *Development of an optimal lidocaine infusion strategy for neonatal seizures*. Eur J Pediatr, 2006. **165**(9): p. 598-604.
97. Lundqvist, M., et al., *Efficacy and safety of lidocaine for treatment of neonatal seizures*. Acta Paediatr, 2013. **102**(9): p. 863-7.
98. Weeke, L.C., et al., *Lidocaine response rate in aEEG-confirmed neonatal seizures: Retrospective study of 413 full-term and preterm infants*. Epilepsia, 2016. **57**(2): p. 233-42.
99. van Rooij, L.G., et al., *Cardiac arrhythmias in neonates receiving lidocaine as anticonvulsive treatment*. Eur J Pediatr, 2004. **163**(11): p. 637-41.
100. Weeke, L.C., et al., *Lidocaine-Associated Cardiac Events in Newborns with Seizures: Incidence, Symptoms and Contributing Factors*. Neonatology, 2015. **108**(2): p. 130-6.
101. Bohnhorst, B., H. Hartmann, and M. Lange, *Severe methemoglobinemia caused by continuous lidocaine infusion in a term neonate*. Eur J Paediatr Neurol, 2017. **21**(3): p. 576-579.
102. Ben-Ari, Y. and G.L. Holmes, *Effects of seizures on developmental processes in the immature brain*. Lancet Neurol, 2006. **5**(12): p. 1055-63.
103. Dzhalala, V.I., et al., *NKCC1 transporter facilitates seizures in the developing brain*. Nat Med, 2005. **11**(11): p. 1205-13.
104. Dzhalala, V.I., A.C. Brumback, and K.J. Staley, *Bumetanide enhances phenobarbital efficacy in a neonatal seizure model*. Ann Neurol, 2008. **63**(2): p. 222-35.
105. Kahle, K.T. and K.J. Staley, *The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures*. Neurosurg Focus, 2008. **25**(3): p. E22.
106. Sullivan, J.E., et al., *Pharmacokinetics of bumetanide in critically ill infants*. Clin Pharmacol Ther, 1996. **60**(4): p. 405-13.
107. Lopez-Samblas, A.M., et al., *The pharmacokinetics of bumetanide in the newborn infant*. Biol Neonate, 1997. **72**(5): p. 265-72.
108. Jullien, V., et al., *Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures*. J Clin Pharmacol, 2016. **56**(3): p. 284-90.

109. Pacifici, G.M., *Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants*. Paediatr Drugs, 2012. **14**(4): p. 233-46.
110. Cleary, R.T., et al., *Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures*. PLoS One, 2013. **8**(3): p. e57148.
111. Mazarati, A., D. Shin, and R. Sankar, *Bumetanide inhibits rapid kindling in neonatal rats*. Epilepsia, 2009. **50**(9): p. 2117-22.
112. Kahle, K.T., et al., *Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1*. J Child Neurol, 2009. **24**(5): p. 572-6.
113. Pressler, R.M., et al., *Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial*. Lancet Neurol, 2015. **14**(5): p. 469-77.
114. Romermann, K., et al., *Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain*. Neuropharmacology, 2017. **117**: p. 182-194.
115. Ormrod, D. and K. McClellan, *Topiramate: a review of its use in childhood epilepsy*. Paediatr Drugs, 2001. **3**(4): p. 293-319.
116. Pulman, J., J.L. Hutton, and A.G. Marson, *Tiagabine add-on for drug-resistant partial epilepsy*. Cochrane Database Syst Rev, 2014(2): p. CD001908.
117. Lyseng-Williamson, K.A. and L.P. Yang, *Topiramate: a review of its use in the treatment of epilepsy*. Drugs, 2007. **67**(15): p. 2231-56.
118. Pressler, R.M. and B. Mangum, *Newly emerging therapies for neonatal seizures*. Semin Fetal Neonatal Med, 2013. **18**(4): p. 216-23.
119. Soul, J.S., *Novel medications for neonatal seizures: Bumetanide and topiramate*. Journal of Pediatric Neurology, 2009. **7**(1): p. 85-93.
120. Battino, D., et al., *Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data*. Clin Pharmacokinet, 2005. **44**(4): p. 407-16.
121. Manitpisitkul, P., et al., *Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study*. Epilepsia, 2013. **54**(1): p. 156-64.
122. Filippi, L., et al., *Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy*. Epilepsia, 2009. **50**(11): p. 2355-61.
123. Filippi, L., et al., *Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI): a feasibility study*. J Matern Fetal Neonatal Med, 2017: p. 1-8.
124. Glass, H.C., C. Poulin, and M.I. Shevell, *Topiramate for the treatment of neonatal seizures*. Pediatr Neurol, 2011. **44**(6): p. 439-42.
125. Novotny, E., et al., *Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures*. Neurology, 2010. **74**(9): p. 714-20.
126. Filippi, L., et al., *Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study*. J Pediatr, 2010. **157**(3): p. 361-6.
127. Glier, C., et al., *Therapeutic doses of topiramate are not toxic to the developing rat brain*. Exp Neurol, 2004. **187**(2): p. 403-9.
128. Walia, K.S., et al., *Side effects of antiepileptics--a review*. Pain Pract, 2004. **4**(3): p. 194-203.
129. Filippi, H., R. Boor, and B. Reitter, *Topiramate and metabolic acidosis in infants and toddlers*. Epilepsia, 2002. **43**(7): p. 744-7.

130. Gunn, A.J., et al., *Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep*. Pediatrics, 1998. **102**(5): p. 1098-106.
131. Schulzke, S.M., S. Rao, and S.K. Patole, *A systematic review of cooling for neuroprotection in neonates with hypoxic ischemic encephalopathy - are we there yet?* BMC Pediatr, 2007. **7**: p. 30.
132. Tagin, M.A., et al., *Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis*. Arch Pediatr Adolesc Med, 2012. **166**(6): p. 558-66.
133. Bennet, L., et al., *Differential effects of hypothermia on early and late epileptiform events after severe hypoxia in preterm fetal sheep*. J Neurophysiol, 2007. **97**(1): p. 572-8.
134. Tooley, J.R., et al., *Head cooling with mild systemic hypothermia in anesthetized piglets is neuroprotective*. Ann Neurol, 2003. **53**(1): p. 65-72.
135. Low, E., et al., *Cooling and seizure burden in term neonates: an observational study*. Arch Dis Child Fetal Neonatal Ed, 2012. **97**(4): p. F267-72.
136. Jacobs, S.E., et al., *Cooling for newborns with hypoxic ischaemic encephalopathy*. Cochrane Database Syst Rev, 2013(1): p. CD003311.
137. Yamamoto, H., et al., *Treatments with midazolam and lidocaine for status epilepticus in neonates*. Brain Dev, 2007. **29**(9): p. 559-64.
138. Ramantani, G., et al., *Levetiracetam: safety and efficacy in neonatal seizures*. Eur J Paediatr Neurol, 2011. **15**(1): p. 1-7.
139. Connell J., et al., *Clinical and EEG response to anticonvulsants in neonatal seizures*. Arch Dis Child, 1989. **64**(4 Spec No): p. 459-64.
140. van Leuven, K., et al., *Midazolam and amplitude-integrated EEG in asphyxiated full-term neonates*. Acta Paediatr, 2004. **93**(9): p. 1221-7.
141. Maytal, J., G.P. Novak, and K.C. King, *Lorazepam in the treatment of refractory neonatal seizures*. J Child Neurol, 1991. **6**(4): p. 319-23.
142. Khan, O., et al., *Role of intravenous levetiracetam for acute seizure management in preterm neonates*. Pediatr Neurol, 2013. **49**(5): p. 340-3

Table 1. Evidence base to date for efficacy of antiseizure drug use in newborn babies

	Case studies with >10 cases	Retrospective studies / prospective trial without cEEG	Prospective trial with cEEG / RCT with insufficient power	RCT
Phenobarbital		{57, 45; 139}	{56, 95}	{43}
Phenytoin		{57; 139}	{56}	{43}
Midazolam	62	{63, 65; 137; 140}	{95}	None
Clonazepam			{56}	None
Diazepam		{139}	None	None
Lorazepam	67	{141}		None
Levetiracetam	81	{82; 138; 142}	{80}	None
Lidocaine		{95; 94; 96-98; 137; 65}	{95}	None
Bumetanide	{112}		{113}	None
Topiramate		{124}	None	None





Legend: RCT: randomized-controlled trial; cEEG: continuous EEG monitoring.

Table 1. Evidence base to date for efficacy of antiseizure drug use in newborn babies


	Case studies with >10 cases	Retrospective studies / prospective trial without cEEG	Prospective trial with cEEG / RCT with insufficient power	RCT
Phenobarbital		Pathak et al 2013 [57] Boylan et al 2002 [45] Connell et al, 1989 [139]	Bye and Flanagan 1995 [56] Boylan et al 2004 [95]	Painter et al 1999 [43]
Phenytoin		Pathak et al 2013 Connell et al, 1989	Bye and Flanagan 1995	Painter et al 1999
Midazolam	Sheth et al 1996	Castro Conde et al 2005 van Leuven et al 2004 Yamamoto et al 200 Shany et al 2007	Boylan et al 2004	None
Clonazepam		Andre et al 1986	Bye and Flanagan 1995	None
Diazepam		Connell et al, 1989	None	None
Lorazepam	Deshmukh et al 1986	Maytal et al 1991		None
Levetiracetam	Rakshasbhuvankar et al 2013	Khan et al 2011 Ramantani et al 2011 Khan et al 2013 Venkatesan 2017	Abend et al, 2011	None
Lidocaine		Hellstrom- Westas et al, 1988 Malingre et al, 2006 Yamamoto et al 2007 Shany et al 2007 Lundqvist et al 2013 van den Broek et al 2013 Weeke et al 2016	Boylan et al 2004	None
Bumetanide	Kahle et al 2009		Pressler et al 2015	None
Topiramate		Glass et al 2011	None	None

Legend: RCT: randomized controlled trial; cEEG: continuous EEG monitoring.

Table 2. Summary of mode of action, PK, efficacy and safety of antiseizure drugs use in newborn babies.

Mode of action	PK data	Adverse events	Efficacy	Dose
<p>Phenobarbital [21; 23; 27-30; 43-45; 95]</p>  <p>Enhancing postsynaptic inhibition by increasing mean open duration of GABA_A receptor</p>	<ul style="list-style-type: none"> - Metabolism: hepatic - T1/2 80-160 h - Cl reduced in HIE - Effect of TH on PK possible 	<ul style="list-style-type: none"> - CNS: sedation, irritability - Respiratory depression - Hypotension - Hepatotoxicity - Possible adverse neuro-developmental outcome 	<ul style="list-style-type: none"> - First line drug worldwide and standard of care - 2 RCT: efficacy in 43-50% - Increase of electro-clinical dissociation 	<ul style="list-style-type: none"> - LD: 20 mg/kg, repeat if required - MD: 5 mg/kg/day - Route: IV, IM, PO
<p>Phenytoin [43; 53; 55-58]</p>  <p>Na⁺</p> <p>Glutamate</p> <p>AMPA/kainate</p>	<ul style="list-style-type: none"> - Metabolism: hepatic - T1/2: 6-200 h (mean 100 h) in 1st wk, 5-10 h in wks 2-4 - First-order kinetics - Drug interactions ++ 	<ul style="list-style-type: none"> - Irritation at injection site (less with Fosphenytoin) - Sedation - Cardiovascular toxicity (arrhythmias) - Hypotension 	<ul style="list-style-type: none"> - Used as second line but limited evidence (1 RCT) - Variable efficacy: 10-50% - Increase of electro-clinical dissociation 	<ul style="list-style-type: none"> - LD: 15-20 mg/kg iv over 20 min - MD: 4-8 mg/kg/day iv - Fosphenytoin: PHT equivalent 1.5 mg/kg - Route: IV, PO
<p>Midazolam [60; 62-66; 69-70; 95; 137]</p>  <p>Enhancing postsynaptic GABA_A inhibition</p> <p>GABA</p> <p>GABA_A</p> <p>Cl⁻</p>	<ul style="list-style-type: none"> - Metabolism: hepatic - T1/2 6-14 h - Pharmacologically active metabolites - Drug interactions + 	<ul style="list-style-type: none"> - Sedation, also agitation - Respiratory depression - Hypotension - Myoclonus - Possible adverse neuro-developmental outcome 	<ul style="list-style-type: none"> - Second line drug - No RCT - Uncontrolled studies with variable efficacy (midazolam: 0-100%) 	<ul style="list-style-type: none"> - LD: 0.05-0.15 mg/kg over 10 min - MD: 0.15-0.5 mg/kg/h (up to 1.0 in one study) - Route: IV
<p>Levetiracetam [78-86; 138]</p>  <p>Reduction of glutamate release via modulation of synaptic vesicle protein 2A (SV2A)</p> <p>SV2A</p> <p>Glutamate</p> <p>AMPA/kainate</p>	<ul style="list-style-type: none"> - T1/2 18 h in 1st wk, 9 h in wks 2-4 - CL is renal and lower in 1st week of life - Drug interactions - 	<ul style="list-style-type: none"> - Sedation - Irritability - In older children adverse effect on behaviour, and rarely hepatotoxicity 	<ul style="list-style-type: none"> - Second line - No RCT - Uncontrolled studies with variable efficacy (30-86%) 	<ul style="list-style-type: none"> - LD: 10-50 mg/kg - MD: 30-50 mg/kg/day - Route: IV, PO

Lidocaine [65; 92-101]




- Metabolism: hepatic
- T_{1/2} 5.2–5.4 h
- Effect of TH on PK
- Active metabolites
- Drug interaction + (phenytoin)

- Cardiac toxicity, particularly arrhythmias
- Sedation
- Hypotension
- Proconvulsive in high doses

- Second line
- No RCT
- Uncontrolled studies with efficacy in 60-78% , less in preterm infants

- LD: 2 mg/kg
- MD: 5-7 mg/kg/h for 4 h, then reduce over 24 hr
- Adapt dose for birth weight & TH
- Route: IV

Bumetanide [105; 108; 112-113; 11-119]




- Metabolism: mostly hepatic, also renal
- T_{1/2} 6-8 h
- Cl influenced by birth weight

- Dehydration with hypotension
- Electrolyte disturbances
- Hyperglycaemia
- Hearing loss

- No evidence of efficacy in neonatal seizures

- Dose as diuretic drug: 0.01-0.05 mg/kg
- Dose as antiseizure drug unknown
- Route: IV, PO

Topiramate [117-129]



- T_{1/2} 36 h
- Cl is mostly renal
- Linear steady state PK
- PK affected by TH
- Drug interaction +

- Sedation
- Irritability
- Feeding problems
- Metabolic acidosis
- Cognitive effects in older children

- Animal data: neuro-protective properties but not confirmed in humans
- No evidence of efficacy in neonatal seizures

- No neonatal dose
- In infants >1 mon: 5-25 mg/kg/day
- Route: PO (no iv preparation)

Legend: Cl: Clearance, HIE: hypoxic ischemic encephalopathy, T_{1/2}: half time, h: hour, LD: loading dose, MD: maintenance dose, TH: therapeutic hypothermia, RCT: randomized controlled trial, IV intravenously, PO per os (by mouth), IM intramuscular.